Logotype for AstraZeneca

AstraZeneca (AZN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for AstraZeneca

Q3 2026 earnings summary

30 Oct, 2026

Executive summary

  • 9M Total Revenue was $46.881bn, up 7% at CER; Core EPS rose 14% to $8.00, supported by broad therapy-area growth.

  • Twelve positive Phase III readouts and four first approvals advanced the pipeline; 2027 readouts represent >$20bn in combined non-risk-adjusted peak-year revenue potential.

  • Ambition 2030 remained on track, with an $80bn risk-adjusted Total Revenue target and 20 NMEs by 2030.

Financial highlights

  • 9M Product Revenue was $46.768bn, up 6% at CER; Alliance Revenue rose 32% to $2.8bn. Q3 Total Revenue was $16.209bn, up 7%.

  • 9M reported operating profit rose 10% to $11.797bn; Core operating profit increased 14% to $16.365bn.

  • 9M reported EPS was $5.62, up 11%; Core EPS was $8.00, up 14%. Q3 Core EPS rose 19% to $2.79.

  • Core gross margin was 83% for 9M and 82% in Q3; 9M reported and core tax rates were 18% and 19%, respectively.

  • 9M operating cash inflow was $10.9bn, down $1.3bn; working capital, higher tax payments and FX effects outweighed higher operating profit. CapEx was $2.3bn.

Outlook and guidance

  • FY 2026 guidance was reiterated: Total Revenue growth at a mid-to-high single-digit percentage and Core EPS growth at a low double-digit percentage, at CER.

  • Core tax rate is expected at 18–22%; core gross margin is expected to be stable to slightly better than 2025.

  • Core R&D expense is expected at the upper end of the low-20% range of Total Revenue; operating expenses are expected to step up sequentially in Q4.

  • FY 2026 CapEx is expected to rise by a low-teens percentage, driven by manufacturing expansion and technology investment.

  • More than 20 key Phase III readouts and pivotal data for nine potential new medicines are expected in 2027; non-risk-adjusted peak-year potential exceeds $20bn.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from AstraZeneca